Revised financials and valuation21 May 2021 10:32
I put this on another threat but it’s worth some discussion on its own.
Long view here....
- assuming a 30 percent hit to dhsc revs for q1. So dhsc revenues revised down to 25m from 36m. This gives total q1 revs of 62m. For the rest of the year I will conservatively keep non dhsc revenues flat. As such I am assuming no upside from snpsig sales, no growth in private sales from airlines and pre flight pcr and most importantly or LFT sales. I have taken The ebitda margin to 58 percent from 68 last year and cash conversion to 50 percent. This gives...
Fy 21 sales 170m
Fy 21 ebitda 99m
Fy 21 ending cash 141m
At SP 370p this gives enterprise value of 120m or an EV EBITDA of 1.2x for 2021.
Assume covid suddenly ends globally for 2022 and we are left as a pure diagnostics biz making sales of tests into the installed q machine base and some other bits and bobs. Say we make a paltry 40m of sales FOR THE WHOLE YEAR at 50 percent ebitda margin so ebitda of 20m and assume neutral free cashflow.
With cash of 141m still this gives fy22 ev ebitda of 5.5x.
Sector trades at 15-20x usually.
The short view....
Help. I’m genuinely interested. The current valuation assumes no dhsc anyway and it also assumes we do nothing with the cash (no m&a, no non covid investment in new products) and it assumes private testing disappears at the end of this year. As such, is this dhsc news priced in? Show me? The SP and valuation seems to be pricing in in this and much much much much downside already IMO. Interested to get the alternative valuation. Not just high level “it’s over” they’re “****ed” but some actual numbers from a shorter. Thanks